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 ABSTRACT: Ionizing radiation (gamma and x-ray) is widely used in industry and medicine, but 
it can also pose a significant hazardous effect on health and induce cancer, physical deformity 
and even death, due to DNA damages and invasion of free radicals. There is therefore an urgent 
unmet demand in designing highly efficient radioprotectants with synergetic integration of 
effective renal clearance and low toxicity. In this study, we designed ultrasmall (sub-5 nm) highly 
catalytically active and cysteine-protected MoS2 dots as radioprotectants and investigated their 
application in protection against ionizing radiation. In vivo preclinical studies showed that the 
surviving fraction of MoS2-treated mice can appreciably increase to up to 79 % when they were 
exposed to high-energy ionizing radiation. Furthermore, MoS2 dots can contribute in cleaning up 
the accumulated free radicals within the body, repairing DNA damages and recovering all vital 
chemical and biochemical indicators, suggesting their unique role as free radical scavengers.  
MoS2 dots showed rapid and efficient urinary excretion with more than 80 % injected dose (I.D.) 
eliminated from the body after 24 hours due to their ultrasmall hydrodynamic size and did not 
cause any noticeable toxic responses up to 30 days. 
 
 
 
 Introduction 
High-energy ionizing radiations (X-rays and gamma rays) are widely used in industry and 
medicine, but these radiations also cause significant health hazards such as cancer and other 
related diseases.1-6 In clinical medicine, more than 50% cancer patients need to receive radiation 
therapies, but high-energy radiations during the treatments not only kill cancer cells but also 
cause inevitable damages to normal tissues.7-8 Besides, more and more nuclear power plants are 
proposed in the world due to the rising demands in energy, imposing potential radiation risks on 
public health.9-10 Under exposures to ionizing radiations, lots of free radicals including reactive 
oxygen species (ROS) are formed through ionizing reactions such as the photoelectric, Compton 
scattering and Auger effects.11-12 These free radicals are able to react with DNA and RNA inside 
the body, cause structural and functional changes and affect biological processes.13-15 As a result, 
it induces cell apoptosis and further triggers cancer or even death. The use of radioprotectants 
provides a feasible solution to shield heath tissues from high-energy radiations.16 Amifostine 
(Ethyol®) is an extensively used prescription radioprotectant in radiation medicine by scavenging 
oxygen-derived free radicals, but its blood elimination half-life is only 1 minute, limiting its 
scavenging activities against ROS.16 Other materials have shown abilities of radiation protection 
to an extent, but they cannot afford effective excretions which could result in potential hepatic 
and splenic toxicities.14-15 As a matter of fact, US Food and Drug Administration (FDA) have 
required all injected agents for in vivo uses to be completely cleared from the body.17 Therefore, 
it is highly desirable to explore an ideal radioprotectant with capabilities of highly efficient 
removals of ROS, renal clearance and low toxicities, for clinical translation as an adjuvant in 
radiotherapies.  
      To address these critical challenges, we utilized a simple approach towards the synthesis of 
ultrasmall cysteine-protected MoS2 dots as radioprotectants. Surface protection with zwitterionic 
 cysteine offers several indispensable merits to the MoS2 dots. Firstly it avoids the significant 
increase in hydrodynamic sizes as compared to other surface ligands and thus allows effective 
elimination from renal clearance.18-19 Secondly, the aqueous dispersibility and stability are 
significantly enhanced by the surface modification, maintaining the ultrasmall size in vivo and 
refraining from aggregation. Last, non-specific adsorption of serum proteins, especially opsonin, 
is largely prohibited, leading to postponed removal from the body and a relatively longer 
circulation time in blood to achieve desired radiation protection. The as-prepared MoS2 dots 
exhibited extraordinary electrocatalytic activities for hydrogen peroxide and oxygen reduction 
reactions (ORRs), leading to lots of free electron transfers. Its endogenous catalytic properties 
provide a promising and effective pathway for scavenging free radicals in vivo via rapid reactions 
with oxygen radical superoxide (O2-) and non-radical oxidant hydrogen peroxide (H2O2) in blood. 
Owing to their strong catalytic activities, MoS2 dots improved the surviving fraction of mice 
exposed to high radiation doses of 662 keV gamma ray. Furthermore, the ultrasmall MoS2 dots 
can indeed eliminate the ROS through reduction reactions in major organs. As a result, 
superoxide dismutase (SOD), as an important indicator for antioxidant defense in almost all 
living cells under exposure to oxygen, nearly recovered back to normal levels, suggesting the 
repair of radiation-induced damages. The ultrasmall cysteine-protected MoS2 dots can be rapidly 
excreted via kidney and did not cause any toxicological responses in 30 days post injection.  
 
Results and Discussion 
      Ultrasmall MoS2 dots were synthesized and purified by a combinational approach of 
ultrasonication and gradient centrifugation according to our published procedures.20-22 However, 
it is difficult to disperse bare MoS2 dots as a stable colloid solution in water, preventing their 
further applications in biological systems. A cysteine protection layer with a molecular weight of 
 121 Da was introduced which not only maintains the ultrasmall hydrodynamic size to meet the 
cut-off size of <5.5 nm for renal clearance,17 but also endows excellent biocompatibility in 
biomedical applications. Cysteine-protected MoS2 dots were obtained and stabilized through the 
chemical bonding and van der Waals interactions between MoS2 and cysteine,23 and were further 
purified and re-dispersed in water (Figure 1a). Obvious Tyndall effects were observed, 
indicative of the existence of small particles in solution. Figure 1b exhibited a representative 
image of transmission electron microscopy (TEM) which showed cysteine-protected MoS2 dots 
have a core size around 2 nm by analyzing 121 dots from TEM images (Figure S1b) and a 
hydrodynamic size of 3.1 nm (Figure S1c) by dynamic light scattering (DLS). X-ray 
photoelectron spectroscopic (XPS) investigation of cysteine-protected MoS2 manifested Mo and 
S elements from MoS2 and N element from cysteine, suggesting the formation of cysteine-MoS2 
composite (Figure 1c). Additionally, the S 2p3/2 binding energy located at 164.0 eV suggested 
the formation of disulfide bonds which are ascribed to the conjugation of cysteine and MoS2 dots 
(Figure 1d).24 On the other hand, no signals from disulfide bonds can be found on the 
corresponding counterparts, cysteine and unprotected MoS2 dots (Figure S2). Optical absorption 
was investigated by UV-vis spectroscopy (Figure 1e). Cysteine alone did not show any 
absorption features, while the MoS2 suspension and cysteine-protected MoS2 dots displayed 
multiple absorption peaks at 393, 470, 607 and 670 nm, attributed to deep energy levels of 
electronic transitions and interband excitonic transitions.25-26  Notably, the results are similar to 
the absorption bands observed for MoS2 particles prepared by other methods.25-26  
We evaluated the in vitro catalytic activities of cysteine-protected MoS2 dots towards 
reduction of H2O2 in N2-saturated 0.01 M phosphate-buffered salin (PBS), pH = 7.4, using a 
cysteine-MoS2 modified glassy carbon electrode (GCE). Figure 1f showed the cyclic 
voltammetric (CV) curves of the ultrasmall cysteine-protected MoS2 dots in the presence and 
 absence of 5.00 mM H2O2 at the scan rate of 50 mV·s−1. Negligible reduction current was 
observed in the absence of H2O2, whereas in the presence of H2O2, the reduction current 
increased sharply when the scan potential shifted to more negative than -0.4 V, indicating 
extraordinary catalytic activities toward reduction of H2O2 compared to voltammetric responses 
of the bare GCE without modification of cysteine-protected MoS2 dots  (Figure S3a). To 
determine the role of cysteine-protected MoS2 dots in oxygen reduction reaction (ORR), CV 
responses of cysteine-protected MoS2 dots were investigated in O2-saturated 0.01 M PBS 
solution at the scan rate of 50 mV·s−1 (Figure 1g). Cysteine-protected MoS2 dots showed 
electrocatalytic activity for reduction of O2 with a more positive onset potential and larger current 
density compared to those of the unmodified GCE (Figure S3b). The electrochemical 
measurements of cysteine-protected MoS2 dots evidenced their strong in vitro catalytic activities 
in H2O2 and oxygen reduction reactions, serving as the original inspiration for us to investigate 
the biological responses in radiation-injured mice.  
We firstly examined the in vitro toxicities of cysteine-protected MoS2 dots in 3T3/A31 cells 
using neutral red assay and MTT method which showed extremely low cytotoxicities with doses 
up to 145 μg/ml (Figure S4). Viabilities of cells treated with cysteine-protected MoS2 dots in 
different doses under exposures to gamma ray were significantly increased compared with those 
without treatments (Figure 2a), suggesting the powerful in vitro protective behaviors of cysteine-
protected MoS2 against radiation. The DNA damages of cysteine-protected MoS2 dots with 
different concentration up to 145 μg/ml also investigated by single-cell sol-gel electrophoresis, 
and no significant difference on tail moments was found, suggesting negligible DNA damages 
from MoS2 dots (Figure S5). DNA damages arising from radiation were further estimated 
(Figure S6). No obvious cell tail moments were found in the control, but cell tails implying 
DNA damages were easily identifiable with exposures to high-energy gamma ray. In contrast, the 
 cell tails from cells treated with cysteine-protected MoS2 dots showed distinct recoveries, 
presenting effective DNA repairs. Quantitative investigations of tail moments showed that cells 
treated with cysteine-protected MoS2 dots recovered to an appreciable degree from exposures of 
gamma ray, as compared to cells treated only with radiation (Figure 2b).  
In vivo protection from radiation using cysteine-protected MoS2 dots were investigated with 
C57BL/6 mice. 200 μL cysteine-protected MoS2 dots at different concentrations were 
intraperitoneally injected into mice. The mice were then exposed to high energy gamma ray 
(137Cs, 3600 Ci) at the dose of 7.5 Gy. The surviving fractions of radiation-injured mice with 
various injection concentrations are shown in Figure 2c. The surviving fraction of mice exposed 
to high-energy radiations without injection of cysteine-protected MoS2 dots is 0 after two weeks. 
This result demonstrated radiation induced acute damages and death which are consistent with 
observations in previous published work.6 With injection of cysteine-protected MoS2 dots, the 
surviving fractions of mice were 7.1 and 42.9 and 78.6 % at the doses of 10, 20 and 50 mg/kg. 
Meanwhile, the surviving fraction of mice treated with cysteine-protected MoS2 dots (200 μL, 5 
mg/ml) in the absence of radiation is 100 %, indicating low toxicities at this concentration. In 
fact, cysteine protection layers were observed to show outstanding biocompatibility, in good 
agreement with previous results.27-28 Besides, we also investigated the in vivo radiation protection 
effects of Pt-, Co- and Ni-doped MoS2 dots as well as cysteine, but none of these metal-doped 
MoS2 dots showed comparable survival rates to that of cysteine-protected MoS2 dots (Figure S7), 
which may be due to the large sizes and different surface chemistries. Noticeably, a low survival 
rate was observed for cysteine-treated mice, clearly providing strong evidences that the radiation 
protection effect against gamma ray is from MoS2 instead of cysteine. Next, DNA damages of 
irradiated mice treated with or without cysteine-protected MoS2 were assessed (Figure 2d). Total 
DNA from bone marrow cells and bone marrow nucleated cells (BMNC), two dominant 
 indicators of ionizing radiation, were collected from control mice, irradiated mice and irradiated 
mice treated with cysteine-protected MoS2. DNA from healthy mice showed an optical density 
(OD) of 0.42 after 1 day, but it drastically decreased to 0.22 only after 1 day post exposure to 
radiation, indicating severe DNA damages induced by radiation. In contrast, OD of total DNA for 
mice treated with cysteine-protected MoS2 dots decreased to a higher value of 0.29 after 1 day. 
After 7 days, OD of mice treated with cysteine-protected MoS2 dots rose to 0.38, almost 
recovered to the healthy value, compared to that of 0.25 from mice with only radiation. These 
results illustrate that cysteine-protected MoS2 dots can effectively decrease DNA damages from 
high-energy radiations. The number of BMNC is presented as in Figure S8. Similar to the results 
of DNA damages, the BMNC number decreased from 6×106 cells/mL in healthy mice to 4.3×106 
cells/mL in irradiated mice after 1 day, while it was recovered to 4.6×106 cells/mL in irradiated 
mice treated with cysteine-protected MoS2 dots. On the 7th day, the BMNC number in mice 
treated with MoS2 dots was stably maintained at 4.6×106/mL as to a significantly decreased level 
of 1.3×106/mL in mice only treated with radiation. The results clearly presented that cysteine-
protected MoS2 dots are critical in recovering the number of BMNC.   
    To address long-term damages caused by radiation, blood chemistry panels of irradiated 
mice under 7 Gy gamma ray were studied (Figure S9). In the beginning (1 day), it is clear that 
white blood cells (WBC), red blood cells (RBC) and platelets (PLT) sharply decreased after 
exposure to gamma ray indicating strong radiation-induced inflammatory responses, independent 
of treatments of cysteine-protected MoS2 dots. At the middle time point (7 days), WBC and PLT 
were still in low levels without distinct recoveries to healthy levels, while all other indicators 
started to display certain recoveries after treatments with cysteine-protected MoS2 dots. After 30 
days, a large number of the indicators of mice treated with irradiation showed significant 
decreases, but those receiving treatments of cysteine-protected MoS2 dots have appreciably 
 recovered to normal levels. Besides, radiation triggered significant changes in levels of alanine 
aminotransferase (ALT) and serum creatinine (CERA) 1 and 7 days post injection (Figure S10). 
On the other hand, all these indicators for MoS2-dot-treated mice were thoroughly restored to 
normal 30 days post injection, while irradiated mice without MoS2 treatments presented 
significant variations in the levels of ALT, albumin (ALB), blood urine nitrogen (BUN) and 
globulin (GLOB). Under exposure to radiations, the acute radiations not only give rise to severe 
DNA breaks and considerable decrease in the BMNC numbers, but also instantaneously elicit 
inflammatory responses.29 Radiation-induced damages were the most severe after 7 days and lots 
of irradiated mice even began to die. After that, the mice started to recover gradually up to the 
30th day. Undoubtedly, radiation always induces certain irreparable damages of DNA and BMNC 
and thus strongly affects the panels of blood chemistry and biochemistry, implying infections and 
inflammations. However, the cysteine-protected MoS2 dots can free the mice from radiation-
related DNA and BMNC damages, relieve corresponding infections and thus increase the overall 
surviving fractions of mice.  
To further reveal the mechanism of the underlying radiation protection, superoxide 
dismutase (SOD) and 3,4-Methylenedioxyamphetamine (MDA) were employed to provide some 
insights. SOD are enzymes that alternately catalyze dismutation (or partitioning) of the 
superoxide (O2−) radicals into either ordinary molecular oxygen (O2) or hydrogen peroxide 
(H2O2). In contrast, MDA is a harmful product generated by mice. The contents of SOD and 
MDA indicate levels of damages caused by ionizing radiation. Figure 3a and b showed SOD 
levels in lung and liver. When mice were exposed to gamma ray, the SOD of lung from all mice, 
independent of treatments of MoS2 dots, notably decreased after 1 day. However, 7 days post 
radiation, the SOD from the mice treated with cysteine-protected MoS2 dots exhibited powerful 
recoveries compared to mice without treatments, clearly elucidating the increase in the ability of 
 ROS clearance. Figure 3c and d examined the MDA levels of lung and liver from irradiated 
mice with or without treatments of cysteine-protected MoS2 dots. The MDA level in the lung of 
normal mice was 8.1 nmol/mL, but it sharply increased to 22.3 nmol/mL after 1 day (Figure 3c). 
In the meantime, the treatment with cysteine-protected MoS2 dots could partially shield the mice 
from radiation damages with much lower MDA levels of 15.1 nmol/mL after 1 day. After 7 days, 
the MDA levels decreased to 10 nmol/mL for mice with treatments of cysteine-protected MoS2 
dots compared to 12.8 nmol/mL for mice only with radiation. Similarly, Figure 3d indicated the 
MDA levels in the liver sharply increased from 3.6 nmol/mL to 13.2 and 12.1 nmol/mL for 
treated and untreated mice, respectively. After 7 days, the mice treated with cysteine-protected 
MoS2 dots recovered back to 4 nmol/mL, but untreated mice was still 5.5 nmol/mL, significant 
higher than the threshold value of normal mice without irradiations. In healthy mice, SOD is 
maintained at normal levels,30-31 but high-energy irradiation is well known to cause generation of 
excessive amount of  ROS and consumption of large quantities of SOD. Consequently, the SOD 
levels from liver and lung decrease enormously. The cysteine-protected MoS2 dots can help to 
get rid of the undesirable hazardous ROS in vivo and rescue the body from consuming lots of 
SOD to achieve the removal of ROS and accordingly, SOD can be recovered and reserved at the 
normal level. Similarly, MDA is normally present in low levels in the body. When mice suffered 
from the exposure to radiation, a large quantity of MDA is produced due to the generation of 
ROS in excess. The cysteine-protected MoS2 dots can decrease MDA levels of mice via 
eliminating free radicals. As such, as the cysteine-protected MoS2 dots with reducing potencies 
circulate into blood, they reduce the radiation-induced ROS, functioning as free radical 
scavengers. 
For further medical applications, pharmacokinetics and biosafety are the two most important 
characteristics to be taken into consideration. We investigated the pharmacokinetics, urine 
 excretion and in vivo toxicities of cysteine-protected MoS2 dots at the injection dose of 50 mg/kg. 
The C57/BL6 mice were injected at the concentration of 5 mg/ml with blood and urine collected 
for pharmacokinetic and renal-excretion studies, as measured by inductively coupled plasma 
mass spectrometry (ICP-MS). Figure 4a shows that the cysteine-protected MoS2 dots has a half 
time of 2.1 hours in blood. Furthermore, nearly 80% of cysteine-protected MoS2 dots can be 
rapidly excreted through the urine route after 24 hours post injection due to their ultrasmall 
hydrodynamic size (Figure 4b and Figure S11). Biodistribution of cysteine-protected MoS2 dots 
was analyzed after 24 hours post injection using ICP-MS. Bladder and kidney showed the highest 
distribution, ascribed to renal clearance, whereas spleen, liver, lung and heart had relatively low 
uptakes (Figure 4c). With increasing post injection time of up to 30 days, the uptakes of MoS2 
dots from all organs sharply decreased as compared to 1 day and MoS2 dots have almost been 
completely eliminated from the body. Traditional nanoparticles with larger sizes cannot be fast 
excreted, inducing high uptakes in liver and spleen.32 For example, carbon nanotubes with PEG 
coatings can only be excreted for a total of 60% after 90 days post injection,33-34 and lots of 
nanotubes accumulated in liver and spleen will induce potential liver toxicities. Noticeably, 
radiation-protective effects of CeO2 and Ag nanoparticles have been previously reported, but all 
those nanomaterials are not clearable by the glomerular filtration of kidney, owing to their large 
sizes as well as active surface chemistries.15, 35 The ultrasmall cysteine-protected MoS2 dots 
shown here, nevertheless, provide the unique feature of highly efficient renal clearance, 
resembling small molecules. 
We next evaluated the in vivo toxicities of cysteine-protected MoS2 dots in terms of body 
weight, immune responses, hematology and biochemistry panels at the time points of 1, 7 and 30 
days. During the 30-day period, treatments with cysteine-protected MoS2 dots did not induce any 
obvious adverse effects on the growth of mice and no meaningful statistical differences were 
 observed in the body weight and the thymus index between the cysteine-protected MoS2 dots-
treated mice and control mice. We examined standard hematological biomarkers including WBC, 
RBC, hematocrit (HCT), mean corpuscular volume (MCV), hemoglobin (HGB), PLT, mean 
corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC). 
Hematological results for the cysteine-protected MoS2 dots are presented in Figure 4d and 
Figure S12a. For the mice treated with cysteine-protected MoS2 dots, two typical indicators 
(WBC, RBC) did not show any meaningful differences from those of untreated mice. These 
results clearly illustrate that the cysteine-protected MoS2 dots do not induce significant infections 
and inflammations in mice and are relatively safe in pre-clinical settings.  
   In addition, we performed the standard biochemistry examination on the mice treated with 
cysteine-protected MoS2 dots at different time points of 1, 7 and 30 days (Figure 4e and Figure 
S12b). The biochemical parameters including ALT, AST, total protein (TP), ALB, blood urea 
nitrogen, CREA, GLOB, and total bilirubin (TBIL) were investigated. We emphasize ALT, AST, 
and CREA, because they are closely related to the functions of liver and kidney of mice. ALT 
showed increase after 7 days, but recovered to normal after 30 days treatments. AST and CREA 
did not have statistical differences in the treated mice. In fact, MoS2 nanosheets and other two-
dimensional nanomaterials have shown potential applications in imaging and photothermal 
therapies, but the hydrodynamic sizes of these particles are too much larger than the 5.5 nm cut-
off value of kidney, which will induce potential liver toxicities.36-43 For example, Au 
nanoparticles coated by PEG and BSA caused acute damages even after 30 days at a relatively 
low injection dose of 5 mg/kg,44-45 In comparison, the sub-5 nm MoS2 dots we prepared with 
efficient renal clearance will escape from the uptake of the reticuloendothelial system (ROS), 
minimizing the toxic effects. The cysteine-protected MoS2 dots showed extremely low liver 
toxicities even at a 10-fold high dose of 50 mg/kg. Finally, the pathological changes of organs 
 were demonstrated by immunohistochemistry at different time points. Liver, spleen, kidney and 
other organs were collected and sliced for Haematoxylin and Eosin (H&E) staining (Figure 4f 
and Figure S13). No apparent damages were observed in all organs, especially the spleen and 
kidney during the entire period.  
       Radiation protection is utmost important in both healthcare and environment. Fukushima 
nuclear radiation has caused detrimental public crisis and irreversible radiation damages in large 
areas.46 Thus, the development of radioprotectants with low toxicities or even without toxicities 
is promising for potential applications in this area. Cysteine-protected MoS2 dots not only endow 
renal clearance, but also offer strong catalytic properties that allow to react with excessive 
radiation-induced ROS in the blood of mice. However, we have conceived that it still has large 
room for the development of new materials for protection from ionizing radiation.  In the future, 
it is valuable to explore new small-molecular organic materials with high activities in free radical 
scavenging. It is necessary to develop effective radioprotectants with sub-5 nm hydrodynamic 
sizes as well as low toxicities.47-54 Besides, it is of great importance to design materials with 
well-defined functional surfaces for radiation protection. It is also interesting to combine features 
of energy transfers and energy-dependent responses under exposure to high-energy radiation. 
Detailed biological and bio-catalytic mechanisms of radiation protection are still necessary to be 
further investigated.55-57 
   
Conclusion 
   In summary, we developed ultrasmall cysteine-protected MoS2 dots radioprotectants, with 
high efficiencies in renal clearance and radiation protection against gamma ray. This type of 
novel nanomaterials behave like organic molecules with low levels of retentions in RES organs 
such as liver and spleen, avoiding associated toxicities. The cysteine-protected MoS2 dots also 
 manifested high catalytic activities against H2O2 and O2, leading to potential removal of ROS in 
vivo. Both in vitro and in vivo experiments showed that the surviving fractions of mice can be 
significantly increased with exposure to high-energy gamma ray. Furthermore, treatments of 
cysteine-protected MoS2 dots can considerably decrease DNA breaks and BMNC damages and 
can also recover radiation-induced damages on WBC, PLT and other vital chemical and 
biological indicators. The cysteine-protected MoS2 dots behave as free radical scavengers and 
induce increase in SOD and decrease in MDA. Finally, we found cysteine-protected MoS2 dots 
achieved around 80% urine excretion via bladder in 24 hours without any observable toxic 
effects even at a high injection dose of 50 mg/kg. 
 
Experimental Section 
Preparation of Ultrasmall Cysteine-protected MoS2 Dots. Firstly MoS2 dots were 
synthesized by a series of ultrasonication and centrifugation steps according to our previous 
work20. MoS2 powder (99%, <2 μm in size, Aldrich) was dispersed in N,N-dimethylformamide 
(DMF) (99.9%, Aldrich) at the concentration of 1 mg mL-1 and then subject to ultrasonication for 
8 h using a SB-2200 sonifier (Shanghai Branson, China) to form a black suspension. The 
resulting suspension was centrifuged at 6000 rpm for 30 min using a high-speed centrifuge 
(Changsha Pingfan Instrument and Meter Co., Ltd., China), with the light yellow supernatant 
collected. It was then centrifuged again at 12000 rpm for 30 min and the precipitated pellets were 
washed with deionized water several times and redispersed in water to form an aqueous 
suspension of MoS2 dots as the unprotected control. As for cysteine-protected MoS2 dots, the 
precipitates were re-dispersed into DMF of the same volume as before centrifugation and L-
cysteine (99%, Beijing Chemical Reagent Co., Ltd.) was added to achieve a final concentration 
of 0.1 mg mL-1. The mixture was mixed uniformly and kept still for 24 hours of aging at room 
 temperature.  Particles in larger sizes were removed by centrifugation at 6000 rpm for 15 min and 
the remaining supernatant was centrifuged again at 12000 rpm for 30 min with the precipitates 
collected. The product was washed extensively with deionized water and centrifuged at 12000 
rpm to remove free cysteine and residual DMF. The solution of cysteine-protected MoS2 dots was 
prepared by redispersing the precipitates into certain volumes of water. 
Preparation of Pt-, Co- or Ni-doped MoS2. The Pt, Co and Ni doped MoS2 (Pt-MoS2, Co-
MoS2 and Ni-MoS2) were synthesized according to our previous work.58 For Pt-MoS2, 900 mg 
(NH4)6Mo7O24·4H2O and 0.442 mL 0.19 mol L-1 H2PtCl6 (aq.) were dissolved in 20 mL 
deionized water to form a homogeneous solution, which were then transferred into a 40 mL 
stainless steel autoclave with 10 mL CS2 under Ar and maintained at 400 oC for 4 h. The 
saturated NaOH (aq.) were used to treat the obtained product at 60 oC for 3 h, followed by 
washing several times with water and absolute ethanol and drying at 100 oC. The Co–MoS2 and 
Ni–MoS2 were synthesized by using 900 mg (NH4)6Mo7O24·4H2O and 0.085 g Co(NO3)2·6H2O 
or 0.084 g Ni(NO3)2·6H2O dissolved in 20 mL deionized water and 10mL CS2, following the 
same process as for Pt–MoS2. The doping contents of Pt, Co and Ni in MoS2 were all 1.7 wt.% 
measured by inductively coupled plasma optical emission spectroscopy (ICP-OES). 
Modification of GCE with Ultrasmall Cysteine-protected MoS2 Dots. Cysteine-
protected MoS2 dots were redispersed in water at the concentration of 1 mg mL-1. Prior to 
modification, GCE was polished with 0.3 μm alumina slurries followed by 0.05 μm alumina 
slurries (Buehler). The polished GCE was sonicated three times, each for 3 min in deionized 
water to remove any residual polishing reagents. The solution of MoS2 was drop casted on GCE 
(diameter = 3 mm) and dried in air with a loading of 0.2 mg cm–2.  
Characterization. All electrochemical measurements were carried out on a CHI 660D 
electrochemical workstation (Chenhua, China) at room temperature. The cysteine- MoS2 dot-
 modified GCE, a Pt electrode and a saturated calomel electrode (SCE) were used as the working, 
counter and reference electrodes respectively for all electrochemical measurements. Transmission 
electron microscopy (TEM) images were acquired on a JEM-2100F electron microscope (JEOL, 
Japan). X-ray photoelectron spectra (XPS) were collected on an Axis Ultra spectrometer (Kratos 
Analytical Ltd., Japan) and the binding energy was calibrated by the C 1s peak at 284.8 eV. UV-
vis absorption spectra were recorded with a U-4100 UV-vis-NIR spectrophotometer (Hitachi, 
Japan). The hydrodynamic diameter of the cysteine-protected MoS2 nanodots was determined by 
dynamic light scattering (DLS) with a NanoZS Zetasizer (Malvern). The sample solutions were 
prepared by dissolving the cysteine-protected MoS2 nanodots in deionized ultrafiltered (DIUF) 
water at a concentration of 0.01 mg/mL. DLS data were acquired in the phase analysis light 
scattering mode at 25 °C and poly-dispersion index is always <0.7 for every measurement.   
In Vitro Cytotoxicity and Radiation Protection. BALB/3T3 clone A31 mouse fibroblasts 
(A31) were employed for cell viability experiments. A31 cells were dispensed in two 96-well 
plates with 7x103 cells per well and incubated under 37℃, 5% CO2 and humidified atmosphere. 
Different concentrations of MoS2 from 0.5-135 μg/ml were introduced into the DMEM culture 
media. After incubation for 24 and 48 hours, cytotoxicities were analyzed with Neutral Red (NR) 
staining. Meanwhile, to further confirm the accuracy of the cell survival rates, cysteine-protected 
MoS2 nanodots were also assessed using MTT Cell Proliferation and Cytotoxicity Assay Kit. 
Cysteine-protected MoS2 dots (final concentrations of 0.5-135 μg/ml) were introduced into the 
DMEM culture media. After 24 or 48 h of treatments, 10 μL of MTT reagent was added to each 
well and incubated for 4 h, and then the media were replaced with 150 μL DMSO to dissolve 
formazan crystals. The optical absorption in 490 nm was measured with a single tube 
luminometer (TD 20/20, Turner Biosystems Inc., Sunnyvale, CA, USA) with the intrinsic optical 
absorption of cysteine-protected MoS2 nanodots subtracted. The cell survival rates were 
 calculated based on the recorded optical absorption. 
4x103 A31 cells were seeded into five 96-well plates, supplemented with high-glucose 
DMEM containing 10% FBS. After 10 hours of incubation, the cells were treated with 0.2 μg and 
2 μg MoS2 dots for 1 hour which were dissolved in 100 ul complete culture media. The five 
plates were then exposed to 0, 2, 4, 8 and 10 Gy radiations respectively. After 48 hours, NR was 
used to evaluate cell viabilities. When cells had sufficiently taken up NR in about~3 hours, the 
media containing NR was discarded and each well was gently washed with 1X PBS, followed by 
addition of 150 μl desorb solution to extract NR from living cells. All the plates were 
homogenized on a microtiter plate shaker for 5 min and the optical absorbance was recorded at 
540 nm by Infinite F200 multimode plate reader.  
In Vitro DNA Damages. The in vitro protocols were approved by the Institutional Review 
Board of Institute of Radiation Medicine at the Chinese Academy of Medical Sciences (CAMS). 
A modified protocol of alkaline COMET assay was used to evaluate DNA damages. Agarose 
(0.8%, 500 μl) was paved homogeneously on glass microscopic slides. After solidification, 4.8 
x104 cells in 30 μL 1X PBS incubated with MoS2 dots (0.5-135 μg/ml) were mixed with 70 μL 
low-melting-point agarose (0.6%) and 20 μl of this mixture was spread over the slide completely. 
The solidified slides were placed into freshly-prepared ice-cold lysis buffer (2.5 mol/L NaCl, 100 
mmol/L Na2EDTA, 10 mmol/L Tris-HCl, 10% DMSO, 1% Triton X-100) for 2 hours, followed 
by immersing them in a horizontal gel electrophoresis unit which was filled with chilled 
electrophoresis buffer (1 mmol/L Na2EDTA, 300 mmol/L NaOH, pH 7.4 for 30 min. 
Electrophoresis was conducted at 30 V for 20 min. The slides were neutralized with ethanol after 
electrophoresis and stained with ethidium bromide (2 μg/mL). DNA damages were analyzed by 
Comet Assay Software Project (CASP) for tail moments. Typically, 100 cells were analyzed for 
DNA tail moment. 
 In Vivo Radiation Protection. All animal-related protocols were reviewed and approved by 
the Institutional Animal Care and Use Committee (IACUC). All animals were purchased, 
maintained and handled under protocols approved by the Institute of Radiation Medicine at the 
Chinese Academy of Medical Sciences (CAMS). 200 μL saline was intraperitoneally injected 
into mice as the control group. As for the treatment group, 1, 2 or 5 mg/mL cysteine-protected 
MoS2 dots were used for animal experiments by intraperitoneal injection with doses of 10, 20 
and 50 mg/kg in mice. Subsequently, the mice were radiated under 7.5 Gy gamma rays (~8 min) 
and 137Cs with an activity of 3600 Ci and a photon energy of 662 KeV were used. 70 mice in total 
were assigned into the following 5 groups (14 mice in each group): control, only treated with 
radiation, treated with both radiation and cysteine-protected MoS2 dots at the doses of 10, 20 and 
50 mg/kg. We then monitored all the mice for up to 30 days and the surviving fractions of mice 
were obtained for each group.  
        Analysis of Total DNA and Bone Marrow Nucleated Cells:  32 male C57BL/6 mice were 
assigned into the following 4 groups (8 mice each group): control of 1 day, treatment group of 1 
day, control of 8 days and treatment group of 8 days. For the control groups, mice were 
administered with 200 μL distilled water and the treatment groups were intraperitoneally injected 
with 200 μl solution of cysteine-protected MoS2 dots at the dose of 50 mg/kg. The entire body of 
each mouse was radiated under gamma ray at the dose of 6.5 Gy. After 1 and 8 days of treatments, 
mice were sacrificed. Bilateral femurs of each mouse were excised from the body and connective 
tissues were removed completely. To estimate the total DNA levels in bone marrows, bone 
marrow cells were flushed from the femurs into calcium chloride solution (10ml, 5 mM) with a 
24-gauge needle and as such, single-cell suspensions were made. The suspensions were placed at 
4℃ for 30 minutes and centrifuged at 2500 rpm/min for 15 minutes with supernatants discarded. 
The pellets were mixed with perchlorate (5 mL 0.2 M) and stored in water bath being heated for 
 15 min at 90℃. After being cooled down to room temperature, the mixtures were purified 
through filter paper (pore size =0.2 μm) and the filtrates were measured for UV-vis absorption at 
268 nm (Shimadzu, UV-1750). Similarly, bone marrow nucleated cells were flushed into 1 mL 
1X PBS, filtered through nylon meshes to remove fragments of bones and tissues for cytometric 
analysis (Mindray BC-2800 Vet). 
     SOD and MDA Analysis: All the organs for SOD and MDA analysis were from identically 
treated mice as for total DNA and BMNC analysis. After 1 and 8 days of treatments, mice were 
sacrificed with livers and lungs collected for analysis of SOD and MDA levels using Total 
Superoxide Dismutase assay kits and Malondialdehyde assay kits (Nanjing Jiancheng 
Bioengineering Institute). All the organs were immersed in saline solution and homogenized with 
a tissue homogenate machine (IKA, T18 basic) to make 10% tissue homogenate. The organ 
homogenates were left on ice for 1 hour and then centrifuged at 3500 r/min for 10 minutes. The 
resulting solutions were further diluted into 1 % and 0.25 % homogenate respectively. For total 
SOD level analysis: phosphate buffer (1 ml, 7.5 mM) was added to 5 ml EP tubes and then mixed 
with liver and lung homogenate (50 μl, 0.25 %) or 50 μl distilled water as control. 
Hydroxylamine hydrochloride (0.1 M, 100 μl), xanthine solution (75 mM, 100 μl) and 
xanthineoxidase solution (0.03 U/L, 100 μl) were added into the above EP tubes in order, fully 
mixed and incubated at 37℃  for 40 minutes. After that, 2ml nitrite developer (C10H9N: 
C6H7NO3S: CH3COOH=3:3:2) was added into the system and analyzed by UV-vis 
spectrophotometer (Shimadzu, UV-1750) at 550 nm. For MDA analysis, 10% tissue 
homogenates were employed. Equal volumes (100 μl) of organ sample, ethanol and 
tetrathoxypropane (10 nmol/ml) were added into individual 5 ml EP tubes, among which ethanol 
and tetrathoxypropane were negative and positive controls respectively. 100 ul tissue lysis 
 solution was added into each 5ml EP tube and mixed completely. Trichloroacetic acid (10 %, 3 
ml) and thiobarbituric acid (0.6 %, 1 ml) were added into the system orderly. Then the tubes were 
heated in water at 95℃ for 40 minutes. After being cooled down to room temperature, all the 
samples were centrifuged at 3500~4000 r/min for 10 minutes with the supernatants analyzed by 
UV-vis spectrophotometer at 532 nm (Shimadzu, UV-1750). 
   In Vivo Toxicity. Animals were purchased, maintained, and handled with protocols 
approved by the Institute of Radiation Medicine, Chinese Academy of Medical Sciences (IRM, 
CAMS). 48 male C57BL/6 mice at the age of 11 weeks were obtained from IRM laboratories, 
housed by 2 mice per cage with a 12 hours/12 hours light/dark cycle and were provided with food 
and water. Mice were randomly divided into 6 groups (8 mice in each group): control of 1 day, 
treatment group of 1 day, control of 7 days, treatment group of 7 days, control of 30 days, and 
treatment group of 30 days respectively. The solution of cysteine-protected MoS2 dots (200 μL, 5 
mg/mL) was used for this animal experiment through intraperitoneal injection. The assigned dose 
was 50 mg/kg in each mouse. Mice were weighed and assessed for behavioral changes every day 
post injection. After treatments with cysteine-protected MoS2 dots for 1, 7 and 30 days, mice 
were sacrificed accordingly at each time point using isoflurane anesthetic and angiocatheter 
exsanguination with 1X PBS. Blood and organs were collected for biochemistry and pathological 
analyses. One mouse from each group was fixed with 10% formalin in PBS following 
exsanguination with PBS. During necropsy, liver, kidneys, spleen, heart, lung, testis, brain, 
bladder and thymus were collected and weighed.  
   Hematology, Biochemistry and Pathology: Using a standard saphenous technique, vein 
blood was collected in potassium EDTA collection tubes for hematological analysis. Standard 
hematological and biochemical examinations were performed. 1 mL of blood was collected from 
mice and separated into cellular and plasma fractions by centrifugation. Mice were sacrificed by 
 isoflurane anesthetic and angio catheter exsanguinations. Major organs were harvested, fixed in 
10% neutral buffered formalin, processed routinely into paraffin and stained by H&E, with 
pathology examined using a digital microscope. 
   Statistical Analyses: Paired Student's t-test was used for statistical analysis between the 
control group and the treatment group (MoS2 alone or radiation+MoS2). The Analysis of 
Variance (ANOVA) was used for statistical analysis among the control, radiation, and 
radiation+MoS2 groups. Differences were considered statistically significant at a P value < 0.05. 
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    Schematic illustration of radiation protection with cysteine-protected MoS2 dots 
  
Figure 1 Characterization and electrocatalytic properties of cysteine-protected MoS2 dots. 
(a) Schematic preparation of cysteine-protected MoS2 dots. (b) TEM image of a population of 
cysteine-protected MoS2 dots with a homogeneous distribution of around 2 nm. Scale bar, 20 nm. 
(c) Wide survey X-ray photoelectron spectrum and (d) S 2p spectrum of cysteine-protected MoS2 
dots. The presence of disulfide bonds indicates the bonding between cysteine and MoS2. Arrows 
show corresponding electronic states in MoS2 dots. (e) UV-vis spectra of aqueous solutions of 
cysteine, unprotected and cysteine-protected MoS2 dots. (f) CVs of GCE modified with cysteine-
protected MoS2 dots in the presence (dotted) and absence (solid) of 5.00 mM H2O2 in N2-
saturated 0.01 M pH 7.4 PBS. Scan rates: 50 mV s–1. (g) CVs of GCE modified with cysteine-
protected MoS2 dots in N2- (solid) and O2-saturated (dotted) 0.01 M pH 7.4 PBS. Scan rate: 50 
mV s−1.  
  
Figure 2 Radiation protection in vitro and in vivo. (a) Radiation dose-dependent protection in 
vitro with different injected doses (50 and 100 μg/mL) or without treatments of cysteine-
protected MoS2 dots. The survival rates of A31 cells with treatments of cysteine-protected MoS2 
dots increased with increasing radiation doses, implying a significant function of protection 
against ionizing radiation in vitro. (b) Cell tail moment of mice with or without treatments of 
cysteine-protected MoS2 dots, suggesting of its role in DNA repairs. Tail moment of DNA 
fragments from single cells receiving 4 Gy radiation was quantitatively calculated by counting 
100 individual healthy and irradiated cells respectively and significant DNA recovery could be 
observed after being treated with cysteine-protected MoS2 dots. (c) Survival curves of mice with 
different doses (10, 20 and 50 mg/kg) or without treatments of cysteine-protected MoS2 dots 
(n=14 mice/group) showing an overall 79% survival proportion after being treated with a dose of 
5 mg/ml. (d) DNA damages of mice 1 and 7 days after treatments of cysteine-protected MoS2 
 dots (n=14 mice/group), as measured by UV-vis absorption at 268 nm. *P<0.05 as compared 
with the control group (paired Student’s t-test).  
  
Figure 3 Mechanisms of protection against radiation. Superoxide dismutase (SOD) levels in 
(a) lung and (b) liver 1 and 7 days after gamma radiation with or without treatments of cysteine-
protected MoS2 dots (n=10 mice/group). 3,4-Methylenedioxyamphetamine (MDA) levels in (c) 
lung and (d) liver 1 and 7 days after gamma radiation with or without treatments of cysteine-
protected MoS2 dots (n=8 mice/group). Both SOD and MDA of the lung and liver recovered to 
healthy levels 7 days after treatments. *P<0.05 as compared with the control group (Student’s t-
test).  
 
  
 
 
Figure 4 In vivo pharmacokinetics, renal clearance, biodistribution and toxicities. (a) Time-
dependent concentrations in blood after intraperitoneal injection (b) Cumulative urine excretion 
at different time points. A large proportion of cysteine-protected MoS2 dots in blood were cleared 
through the renal route. (c) Biodistribution of cysteine-protected MoS2 dots at 24 hours and 30 
days post injection. %ID/g=percentage of the injected dose per gram of weight. (d) 
Hematological data of RBC and WBC in mice treated with cysteine-protected MoS2 dots. Data 
were collected at different time points of 1, 7 and 30 days after intraperitoneal injection (50 
mg/kg). (e) Blood biochemistry analysis of mice treated with the cysteine-protected MoS2 dots at 
different time points of 1, 7 and 30 days after treatments. *P<0.05 as compared with the control 
group (Student’s t-test). (f) Pathological evaluation of liver, spleen and kidney of mice treated 
 with cysteine-protected MoS2 dots. (n=8 mice/group) collect at different time points of 1, 7 and 
30 days post injection. Scale bars, 50 μm.  
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Figure S1 (a) Schematic structure (not to scale) and (b) core size distribution of cysteine-
protected MoS2 dots measured by analyzing 121 nanodots from TEM images. (c) Hydrodynamic 
size of cysteine-protected MoS2 dots measured by DLS.  
  
 
Figure S2 XPS spectra of S 2p region for (a) unprotected MoS2 dots and (b) cysteine. No 
disulfide states could be observed in both cases. 
. 
 
  
Figure S3 Electrocatalytic activities of unmodified GCE. (a) CVs of unmodified GCE with 
(dotted) or without (solid) addition of 5.00 mM H2O2 in N2-saturated 0.01 M pH 7.4 PBS, (b) 
CVs of unmodified GCE in N2- (solid) and O2-saturated (dotted) 0.01 M pH 7.4 PBS. Scan rate: 
50 mV s−1. The electrocatalytic measurements indicate low reduction activities of unmodified 
GCE against H2O2 and O2 without modification of cysteine protected-MoS2 dots. Note that the 
as-shown current densities are in a much smaller scale than in Figure. 1. 
  
Figure S4 Evaluation of cytotoxicities on cysteine-protected MoS2 dots. In vitro cytotoxicities 
of cysteine-protected MoS2 dots on A31 mouse fibroblasts estimated by (a) Neutral Red assays 
and (b) MTT assays. The results were consistent and demonstrated low cytotoxicities of cysteine-
protected MoS2 dots. 
  
Figure S5 Evaluation of DNA damages on cysteine-protected MoS2 dots. In vitro images of 
comet assays on A31 cells treated with different concentrations of MoS2 dots (0.5-135 μg/ml) 
and (h) corresponding tail moment analysis. 
  
Figure S6 (a-c) Images of untreated control A31 cells, cells treated with only radiation and 
cysteine-protected MoS2 dots plus radiation. The scale bar represent 100 μm. 
  
Figure S7 (a) Schematic diagram showing Pt-, Co- or Ni-doped MoS2 dots. (b) Hydrodynamic 
sizes of different metal-doped MoS2 dots. (c) Body weight and (d) survival curves of mice 
treated with Pt-, Co-, Ni-doped MoS2 dots and cysteine at a dose of 50 mg/kg under exposure to 
gamma ray. Compared with cysteine-protected MoS2 dots, neither metal doping in MoS2 dots nor 
pure cysteine showed increased survival proportions or reservation in body weight (n=10 
mice/group). 
 
 
 
 
 
  
 
Figure S8 Effects on BMNC. Counts of bone marrow nucleated cells in control mice, mice only 
treated with radiation and mice treated with radiation and cysteine protected-MoS2 dots at the 
dose of 50 mg/kg. Treatments of cysteine-protected MoS2 dots almost restored BMNC was to 
normal levels. *P<0.05 as compared with the control group (Student’s t-test).  
  
 
 
Figure S9 In vivo radiation protection of cysteine-protected MoS2 dots. (a) Hematological 
analysis of irradiated mice treated with or without cysteine-protected MoS2 dots. Data were 
collected at different time points of 1, 7 and 30 days after intraperitoneal injection (50 mg/kg, 
n=10 mice/group). The results included red blood cells (RBC), white blood cells (WBC), 
platelets (PLT), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin 
concentration (MCHC), mean corpuscular volume (MCV), hemoglobin (HGB), and hematocrit 
(HCT). Data were analyzed using Student’s t-test and * in (a) and (b) indicates p < 0.05.  
 
 
 
  
 
Figure S10 In vivo radiation protection of cysteine-protected MoS2 dots. (b) Blood 
biochemistry analysis of irradiated mice treated with or without cysteine-protected MoS2 dots at 
different time points of 1, 7 and 30 days (50 mg/kg, n=10 mice/group). The results showed mean 
and standard deviation of alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
total protein (TP), albumin (ALB), blood urea nitrogen (BUN), creatinine (CREA), globulin 
(GOLB) and total bilirubin (TBIL). The results from hematology and biochemistry panels 
showed the cysteine-protected MoS2 dots can recover the indicators 30 days post injection. Data 
were analyzed using Student’s t-test and * in (a) and (b) indicates p < 0.05.  
 
  
 
Figure S11 Time-course renal clearance of cysteine-protected MoS2 dots. Time-dependent 
concentrations of cysteine-protected MoS2 dots (50 mg/kg) in urine of mice at different time 
points post injection, measured by ICP-MS. 
 
  
 
 
Figure S12 In vivo toxicities of cysteine-protected MoS2 dots. (a) Hematological data of mice 
treated with cysteine protected-MoS2 dots. Data were collected at different time points of 1, 7 
and 30 days after intraperitoneal injection (50 mg/kg, n=8 mice/group). The results included PLT, 
MCH, MCHC, MCV, HGB, and HCT.(b) Blood biochemistry analysis on mice treated with 
cysteine-protected MoS2 dots at different time points of 1, 7 and 30 days. The results showed 
mean and standard deviation of TP, ALB, BUN, CREA, GOLB, and TBIL. Data were analyzed 
using Student’s t-test and * in (a) and (b) indicates p < 0.05.  
 
 
 
 
 
 
  
Figure S13 Representative pathological analysis for bladder, lung, heart and testis of mice 
treated with cysteine-protected MoS2 dots (50 mg/kg, n=8 mice/group) at different time points of 
1, 7 and 30 days. Scale bars, 50 µm.  
  
 
